MMRF invests $1M to advance DCT’s new CAR T-cell therapy
Through its Myeloma Investment Fund, the Multiple Myeloma Research Foundation (MMRF) has invested $1 million in novel CAR T-cell technology from Dynamic Cell Therapies (DCT) that aims to better treat multiple myeloma. Backed by this investment, DCT remains on track to move a new CAR T-cell…